Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

1. Castellano, D.
2. Capdevila, J.
3. Sastre, J.
4. Alonso, V.
5. Llanos, M.
6. García-Carbonero, R.
7. Manzano Mozo, J.L.
8. Sevilla, I.
9. Durán, I.
10. Salazar, R.